Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 Dose-Ranging Study for Moderate to Severe Glabellar Lines
NCT04096326Phase 2Completed
- Sponsor
- Allergan
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trenibotulinumtoxinE in glabellar lines (10 cohorts), sponsored by Allergan. Primary endpoint: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS at Day 7. Started Sep 2019; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04096326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096326.